798P - Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advance...
Date | 09 October 2016 |
Event | ESMO 2016 Congress |
Session | Poster display |
Topics | Urothelial Cancers |
Presenter | Aristotelis Bamias |
Citation | Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373 |
Authors |
A. Bamias1, K. Tzannis1, M. Liontos2, L. Harshman3, S.J. Crabb4, Y. Wong5, S.K. Pal6, T.B. Powles7, J. Bellmunt8, U. De Giorgi9, S. Ladoire10, N. Agarwal11, E.Y. Yu12, G. Niegisch13, C.N. Sternberg14, A. Alva15, S. Srinivas16, J. Rosenberg17, R. Investigators18
|
Abstract
Background
Cisplatin-based chemotherapy is the treatment of choice in mUC. A significant proportion of patients do not receive chemotherapy, while about 50% of treated patients do not receive cisplatin. We used the multinational RISC database to map patterns of chemotherapy utilization and adherence to recently published UFC criteria (Galsky, 2011) in unselected mUC patients
Methods
Selection criteria: diagnosis of mUC, transitional-cell, mixed, squamous and adeno histologies.
Results
Of 1974 mUC patients 475 (25%) did not receive 1st-line chemotherapy. No chemotherapy administration was associated with: non-pure TCC histology, higher Charslon Comorbidity Index (CCI), non-caucasian race, non-european country, low volume center (contribution of
Conclusions
Patterns of practice are influenced by various factors, such as age, co-morbidities, race, country of origin and volume of mUC patients. 25% of non-cisplatin treated patients were fit-for-cisplatin. Age and co-morbidities represent major factors, which lead to deviation from the established UFC criteria.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
Icahn School of Medicine, Mount Sinai USA
Disclosure
All authors have declared no conflicts of interest.